# API5

## Overview
API5, or apoptosis inhibitor 5, is a gene that encodes a nuclear protein involved in the regulation of apoptosis and cell survival. The protein, also referred to as API5, functions as an apoptosis inhibitor by interacting with various apoptotic pathways and cellular processes. It is characterized by several functional domains, including a Nuclear Localization Signal and a leucine zipper domain, which facilitate its nuclear transport and protein-protein interactions, respectively (Basset2017Api5; Kuttanamkuzhi2023Altered). API5 plays a significant role in modulating the transcriptional activity of key factors such as E2F1, thereby influencing cell cycle progression and proliferation (GarciaJove2013Api5). Additionally, API5 is implicated in mRNA export and interacts with components of the mRNA export machinery, contributing to cellular homeostasis (Abbas2024Apoptosis). The protein's involvement in cancer progression and resistance to therapy underscores its clinical significance, making it a potential target for therapeutic interventions (Abbas2024Apoptosis).

## Structure
The API5 protein, also known as apoptosis inhibitor 5, is a 55 kDa protein localized in the nucleus and characterized by several functional domains. It contains a Nuclear Localization Signal (NLS) from amino acids 454 to 475, which facilitates its transport into the nucleus (Basset2017Api5; Kuttanamkuzhi2023Altered). The protein also features a leucine zipper domain from amino acids 370 to 391, which is often involved in protein-protein interactions (Basset2017Api5). A critical LXXLL motif, located from amino acids 102 to 106, is essential for its interaction with estrogen receptor alpha (ERα) in the nucleus, playing a significant role in breast cancer outcomes (Basset2017Api5).

API5 is known to interact with the C domain of ERα, which includes the DNA Binding Domain, through its LXXLL motif, contributing to the transcriptional activation of ERα target genes (Basset2017Api5). The protein's overexpression is linked to tumorigenicity and migration in breast cancer, and its downregulation can suppress tumor growth (Basset2017Api5). While specific details on the primary, secondary, tertiary, or quaternary structures of API5 are not provided, its functional domains and interactions suggest a complex role in cellular processes.

## Function
API5, or apoptosis inhibitor 5, is a nuclear protein that plays a crucial role in inhibiting apoptosis, thereby promoting cell survival. It achieves this by interacting with various apoptotic pathways, including the inhibition of Acinus-mediated apoptotic DNA fragmentation and caspase-2 activation (Abbas2024Apoptosis; Han2012Helical). API5 also modulates the transcriptional activity of the E2F1 transcription factor, which is essential for the G1/S phase transition in the cell cycle. Although API5 does not directly interact with E2F1, it enhances E2F1's ability to bind to its target gene promoters, thereby facilitating cell cycle progression and proliferation (GarciaJove2013Api5).

API5 is involved in the regulation of mRNA export from the nucleus to the cytoplasm, interacting with components of the mRNA export machinery, such as UAP56, and being part of the transcription/export (TREX) complex (Abbas2024Apoptosis). The protein's activity is regulated by post-translational modifications, including acetylation, which affects its stability and subcellular localization (Sharma2020Interplay). Through these molecular processes, API5 contributes to cellular homeostasis and organismal development by ensuring proper cell cycle progression and survival under stress conditions (Abbas2024Apoptosis).

## Clinical Significance
Alterations in the expression of the API5 gene have significant clinical implications, particularly in cancer. Overexpression of API5 is associated with aggressive tumor behavior, resistance to therapy, and poor prognosis in various cancers, including breast, colorectal, cervical, and non-small cell lung cancer, as well as B-cell chronic lymphoid leukemia (Abbas2024Apoptosis). API5's role in cancer progression is linked to its ability to inhibit apoptosis, promote tumor invasion, and facilitate metastasis through mechanisms such as the epithelial-mesenchymal transition (EMT) and the upregulation of matrix metalloproteinases (MMPs) (Abbas2024Apoptosis).

API5 also contributes to chemoresistance in cancer cells, particularly through the API5/FGFR1/ERK/BIM axis, which is conserved across multiple cancers (Abbas2024Apoptosis). This axis involves the degradation of the proapoptotic protein BIM, aiding in tumor cell survival and immune escape (Abbas2024Apoptosis). Targeting API5 has been proposed as a therapeutic strategy, with approaches including RNA interference, direct degradation, and disruption of protein-protein interactions showing potential in increasing cancer cell sensitivity to anticancer agents (Abbas2024Apoptosis).

In the context of Crohn's disease, API5 is identified as a protective factor for Paneth cells in individuals with ATG16L1 deficiency, suggesting its potential as a therapeutic target in inflammatory bowel disease (MatsuzawaIshimoto2022The).

## Interactions
API5, or apoptosis inhibitor 5, is involved in various protein-protein interactions that contribute to its role in inhibiting apoptosis and promoting cell survival. API5 interacts with high molecular mass forms of fibroblast growth factor 2 (FGF-2) in the nucleus. This interaction is facilitated by specific regions of API5, including the α6 and α15-α16 regions, which are important for binding FGF-2 (Han2012Helical). API5 also binds to Acinus, a nuclear factor involved in apoptotic DNA fragmentation, protecting it from cleavage by caspase-3, thereby inhibiting apoptosis (Abbas2024Apoptosis).

API5 is implicated in the regulation of mRNA export through its interaction with FGF-2, forming a complex that interacts with UAP56, an RNA helicase essential for mRNA export (Abbas2024Apoptosis). API5 also interacts with TLR4, a member of the Toll-like receptor family, triggering the TLR4-NF-kB pathway and leading to dendritic cell maturation and activation (Abbas2024Apoptosis).

API5's interaction with the FGF2/FGFR1 signaling pathway is crucial for tumor cell survival, as it activates ERK signaling, preventing apoptosis and contributing to immune resistance in tumor cells (Noh2014API5). These interactions highlight API5's role as a molecular hub in various cellular processes.


## References


[1. (MatsuzawaIshimoto2022The) Yu Matsuzawa-Ishimoto, Xiaomin Yao, Akiko Koide, Beatrix M. Ueberheide, Jordan E. Axelrad, Bernardo S. Reis, Roham Parsa, Jessica A. Neil, Joseph C. Devlin, Eugene Rudensky, M. Zahidunnabi Dewan, Michael Cammer, Richard S. Blumberg, Yi Ding, Kelly V. Ruggles, Daniel Mucida, Shohei Koide, and Ken Cadwell. The γδ iel effector api5 masks genetic susceptibility to paneth cell death. Nature, 610(7932):547–554, October 2022. URL: http://dx.doi.org/10.1038/s41586-022-05259-y, doi:10.1038/s41586-022-05259-y. This article has 34 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41586-022-05259-y)

[2. (Kuttanamkuzhi2023Altered) Abhijith Kuttanamkuzhi, Debiprasad Panda, Radhika Malaviya, Gautami Gaidhani, and Mayurika Lahiri. Altered expression of anti-apoptotic protein api5 affects breast tumorigenesis. BMC Cancer, April 2023. URL: http://dx.doi.org/10.1186/s12885-023-10866-7, doi:10.1186/s12885-023-10866-7. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-023-10866-7)

[3. (GarciaJove2013Api5) Marina Garcia-Jove Navarro, Céline Basset, Tania Arcondéguy, Christian Touriol, Guillaume Perez, Hervé Prats, and Eric Lacazette. Api5 contributes to e2f1 control of the g1/s cell cycle phase transition. PLoS ONE, 8(8):e71443, August 2013. URL: http://dx.doi.org/10.1371/journal.pone.0071443, doi:10.1371/journal.pone.0071443. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0071443)

[4. (Abbas2024Apoptosis) Hafsia Abbas, Dalia Kheira Derkaoui, Louise Jeammet, Emilie Adicéam, Jérôme Tiollier, Hélène Sicard, Thorsten Braun, and Jean-Luc Poyet. Apoptosis inhibitor 5: a multifaceted regulator of cell fate. Biomolecules, 14(1):136, January 2024. URL: http://dx.doi.org/10.3390/biom14010136, doi:10.3390/biom14010136. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biom14010136)

[5. (Noh2014API5) Kyung Hee Noh, Seok-Ho Kim, Jin Hee Kim, Kwon-Ho Song, Young-Ho Lee, Tae Heung Kang, Hee Dong Han, Anil K. Sood, Joanne Ng, Kwanghee Kim, Chung Hee Sonn, Vinay Kumar, Cassian Yee, Kyung-Mi Lee, and Tae Woo Kim. Api5 confers tumoral immune escape through fgf2-dependent cell survival pathway. Cancer Research, 74(13):3556–3566, June 2014. URL: http://dx.doi.org/10.1158/0008-5472.can-13-3225, doi:10.1158/0008-5472.can-13-3225. This article has 48 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-13-3225)

6. (Sharma2020Interplay) Interplay between p300 and HDAC1 regulate acetylation and stability of Api5 to regulate cell proliferation. This article has 0 citations.

[7. (Basset2017Api5) Céline Basset, Florence Bonnet-Magnaval, Marina Garcia-Jove Navarro, Christian Touriol, Monique Courtade, Hervé Prats, Barbara Garmy-Susini, and Eric Lacazette. Api5 a new cofactor of estrogen receptor alpha involved in breast cancer outcome. Oncotarget, 8(32):52511–52526, April 2017. URL: http://dx.doi.org/10.18632/oncotarget.17281, doi:10.18632/oncotarget.17281. This article has 13 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.17281)

[8. (Han2012Helical) Byeong-Gu Han, Kyoung Hoon Kim, Sang Jae Lee, Kyung-Chae Jeong, Jea-Won Cho, Kyung Hee Noh, Tae Woo Kim, Soon-Jong Kim, Hye-Jin Yoon, Se Won Suh, Sangho Lee, and Byung Il Lee. Helical repeat structure of apoptosis inhibitor 5 reveals protein-protein interaction modules. Journal of Biological Chemistry, 287(14):10727–10737, March 2012. URL: http://dx.doi.org/10.1074/jbc.m111.317594, doi:10.1074/jbc.m111.317594. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m111.317594)